LSE:SN 14 May 2026 - 3 July 2026

Smith & Nephew (LON:SN) buyback tops dilution; shares lag FTSE 100
·

Smith & Nephew (LON:SN) buyback tops dilution; shares lag FTSE 100

London was closed Friday, so Smith & Nephew plc heads into Monday with a reduced share count and no change on the day. The main question for investors after the first-quarter report in May is still about U.S. knees: will growth there in the second half meet the 2026 targets? Smith & Nephew finished Friday at 1,127p, adding 0.50p for the day. The stock lagged the FTSE 100, according to AJ Bell. Market cap stood near 9.52 billion pounds. The year's range is 1,050p to 1,441.50p.
July 4, 2026
Smith & Nephew (LON:SN) buyback makes headlines as U.S. knees keep pressure on
·

Smith & Nephew (LON:SN) buyback makes headlines as U.S. knees keep pressure on

Smith & Nephew plc finished Friday little changed, but trading screens saw more action in the buyback column. The medical tech firm said in a Friday RNS it repurchased 1,592,090 shares between June 26 and July 2, paying a volume-weighted average price of £11.1447 on the London Stock Exchange. Since May 8, the company has bought back 10,668,678 shares, spending $160.4 million. That leaves about $89.6 million on the first $250 million piece of the buyback, now 64% used up. The tranche is tied to the $500 million repurchase laid out with first-quarter earnings, which Smith+Nephew said they would finish inside 12 months using free cash flow and existing cash.
July 3, 2026
Smith & Nephew (LON:SN) drops after Cevian lifts stake, growth gap lessens
·

Smith & Nephew (LON:SN) drops after Cevian lifts stake, growth gap lessens

Smith & Nephew plc dropped 4.63% on Tuesday to finish at 1,090.50p, while the FTSE 100 added 0.12%. Hargreaves Lansdown reported trading volume at 5.95 million shares and a market value of £9.22 billion. London trade had closed by the time of this report. Smith & Nephew shares fell the same day the company filed a U.S. Form 6-K, reporting that Cevian Capital II GP Limited upped its voting rights stake to 13.206621%, or 111,788,454 voting rights. The filing lists the previous position as 13.056468%, and says no new notification threshold was triggered.
June 30, 2026
Cevian’s holding in Smith & Nephew tops buyback as knee recovery in focus
·

Cevian’s holding in Smith & Nephew tops buyback as knee recovery in focus

Smith & Nephew plc inched up 0.44% to 1,143.5p as of 12:51 BST on Monday, according to LSEG figures from Investors Chronicle. Shares are up just 3.11% over the last year—slightly higher, but not much for a FTSE 100 healthcare name. The stock holds a mixed outlook: three buys, four outperform calls, and 11 holds as of June 25. The headline story isn't just today's share price. The focus is on the standoff between an activist stake and the company’s buyback program. Cevian Capital II GP Limited told Smith & Nephew it passed a new mark on June 23, bringing its voting rights to 13.056468%, or 110,517,469 votes, all direct—no financial instruments involved.
June 29, 2026
Smith & Nephew (LON:SN) shares underperform as Cevian stake rises above 13%, buyback passes midpoint
·

Smith & Nephew (LON:SN) shares underperform as Cevian stake rises above 13%, buyback passes midpoint

Smith & Nephew plc is heading into next week with its buyback still running near the market. Funds tied to Cevian have taken their voting stake past 13%, bringing capital returns and governance issues back to the front. Shares ended Friday’s session at 1,138.5p, down 0.65% after trading wrapped in London. Cevian Capital II GP Limited increased its stake to 13.056468%, or about 110.5 million voting rights, after crossing a threshold on June 23, according to a Form 6-K filed June 25. That's up from 12.235936% earlier. The filing said Cevian held no position via financial instruments.
June 28, 2026
Smith & Nephew Shares Hold Steady as Buyback and Cevian Stake Keep Turnaround in Focus
··

Smith & Nephew Shares Hold Steady as Buyback and Cevian Stake Keep Turnaround in Focus

Smith & Nephew plc shares were almost flat in London on Monday, with Hargreaves Lansdown showing the stock at a 1,134p sell price and 1,135p buy price, up 1.5p, or 0.13%, while the FTSE 100 was down 0.32%. The move was small, but it mattered because the medical technology group remains in a tug of war between shareholder-return support and doubts about the speed of its turnaround. The same quote showed a market value of about £9.61 billion, a price-to-earnings ratio of 14.94 and a 2.56% dividend yield. A price-to-earnings ratio, or P/E, compares a company’s share price with its earnings and is often used as a quick valuation check. The latest support for the stock comes from Smith &
June 15, 2026
Smith & Nephew Faces Fresh Cevian Pressure After Activist Stake Tops 11%
·

Smith & Nephew Faces Fresh Cevian Pressure After Activist Stake Tops 11%

Cevian Capital bumped its holding in Smith & Nephew plc to a little above 11% of voting rights, according to a regulatory notice released Thursday. The move ramps up activist pressure on the British medical technology company, which has faced a sluggish opening stretch this year. Cevian Capital II GP Limited upped its stake in Smith & Nephew, according to a TR-1 filing, after pushing past a key threshold on May 11. The firm alerted Smith & Nephew two days later, with its position now at 11.013663%, up from 10.094356%. That’s 94.1 million voting rights.
May 14, 2026